Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study by Soo Jung Kim et al.
RESEARCH ARTICLE Open Access
Characteristics associated with progression
in patients with of nontuberculous
mycobacterial lung disease : a prospective
cohort study
Soo Jung Kim1, Soon Ho Yoon2, Sun Mi Choi3, Jinwoo Lee3, Chang-Hoon Lee3, Sung Koo Han3
and Jae-Joon Yim3*
Abstract
Background: Patients with distinctive morphotype were more susceptible to nontuberculous mycobacterial lung
disease (NTM-LD). However, little is known about the association between body morphotype and progression of
NTM-LD. The aim of this study was to elucidate predictors of NTM-LD progression, focusing on body morphotype
and composition.
Methods: Data from patients with NTM-LD who participated in NTM cohort which started in 1 July 2011 were analyzed.
Patients with more than 6 months of follow up were included for analysis. NTM-LD progression was defined as clinician-
initiated anti-NTM treatment, based on symptomatic and radiologic aggravation. Body morphotype and composition was
measured at entry to the cohort using bioelectrical impedance analysis.
Results: NTM-LD progressed in 47 out of 150 patients with more than 6 months of follow up. Patients with middle
(adjusted hazard ratio [aHR], 2.758; 95% confidence interval [CI], 1.112–6.843) or lowest tertile (aHR, 3.084; 95% CI, 1.241–7.
668) of abdominal fat ratio had a higher risk of disease progression compared with the highest tertile. Other predictors for
disease progression were presence of cavity on chest computed tomography (aHR, 4.577; 95% CI, 2.364–8.861), and
serum albumin level <3.5 g/dL (aHR, 12.943; 95% CI, 2.588–64.718).
Conclusions: Progression of NTM-LD is associated with body composition. Lower abdominal fat ratio is an independent
predictor of NTM-LD progression.
Trial registration: ClinicalTrials.gov, NCT01616745 Registered 25 March 2012
Keywords: Abdominal fat, Anthropometry, Body composition, Nontuberculous mycobacteria
Background
Nontuberculous mycobacterial lung disease (NTM-LD)
has been increasing prevalence in many part of the
world [1–4]. Unlike Mycobacterium tuberculosis (TB),
the diagnosis of NTM-LD does not necessitate initiation
of therapy, and treatment should be decided based on
the potential risks and benefits of therapy for individual
patients [1]. Previous reports have indicated that about
half of patients with Mycobacterium avium complex
(MAC) lung disease required treatment eventually [5, 6].
Given the difficulties in predicting which patients with
NTM-LD will experience disease progression, an obser-
vation period is usually needed to decide whether or not
to initiate treatment [7, 8]. In MAC lung disease, the
presence of cavities or consolidation on initial chest
computed tomography (CT) was suggested to be associ-
ated with disease progression and treatment [5]. Thinner
chest subcutaneous fat thickness on chest CT or higher
number of involved lung segments were also suggested
as risk factors for radiologic deterioration [9]. Another
study demonstrated that patients with M. intracellulare
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lung disease, positive sputum smears, or fibrocavitary form
were more likely to receive anti-NTM treatment [10].
It has been shown that patients with a distinctive body
morphotype are more susceptible to NTM-LD; patients
with pulmonary NTM infection were taller and leaner
than controls, while skin fold and circumference measure-
ments were also significantly leaner [11]. In addition,
lower body mass index (BMI) [12, 13], lower percent body
fat and total body fat [12], and low subcutaneous fat [14]
have been reported among patients with NTM-LD.
However, little is known about the association between
body morphotype or composition and the progression of
NTM-LD. The objective of the present study was to elu-
cidate the impact of body morphotype and composition
on the progression of NTM-LD through analysis of a
prospective cohort of patients with NTM-LD.
Methods
Participants
Patients with NTM-LD who participated in a previously
described ongoing observational, prospective study [13],
which begun on 1 July 2011 at Seoul National University
Hospital were included and analyzed. Study inclusion
criteria were: aged between 20 and 80 years, NTM-LD
that fulfilled the diagnostic criteria reported in the 2007
American Thoracic Society/Infectious Diseases Society
of America guidelines [1]. Patients previously treated for
NTM-LD were excluded from this study. The clinical
trial registration number for the study is NCT01616745
(www.ClinicalTrials.gov). All patients provided written
informed consent before enrollment. Retrieval of data
for the current study was performed on 1 April 2015.
Patients followed for fewer than 6 months, and patients
without follow-up CT scans, were excluded.
Study design
At study enrollment of the participants, demographic,
clinical, laboratory, and radiographic data, and body
morphotype characteristics were collected and analyzed.
Body morphotype and composition including height,
weight, BMI, total body muscle, total body fat, percent-
age body fat, abdominal fat ratio, waist circumference,
and hip circumference were measured using InBody 720
(Biospace Co, Seoul, South Korea) which utilized the
bioelectrical impedance analysis method. This body
composition analyzer assumes the body comprises five
cylinders: four limbs and the trunk, and measures im-
pedance of these parts separately. This method provides
segmental measurement of body water and fat-free mass.
The abdominal fat ratio is the ratio of fat stored in the
waist to fat stored in the hips. Each morphometric meas-
urement was categorized according to tertiles for ana-
lysis. The levels of adipokines were also measured at
study entry. Serum level of leptin was measured using
radioimmunoassay (RIA) kit (LINCO Research, Inc.,
U.S.A) and serum level of adiponectin was measured
using an enzyme-linked immunosorbent assay (ELISA)
kit (Biovendor, Brno, Czech Republic).
All patients had a chest CT scan at study entry. CT
scans were evaluated by a board-certified radiologist using
a previously published scoring system [15]. A total of six
lung lobes (right upper lobe, right middle lobe, right lower
lobe, upper division of the left upper lobe, lingular division
of the left upper lobe, and left lower lobe) in each patient
were assessed for the presence of lung parenchymal ab-
normalities. Scores were assigned by considering the pres-
ence, severity, and extent of bronchiectasis (maximum
score, 9), cellular bronchiolitis (maximum score, 6), cavity
(maximum score, 9), nodules (maximum score, 3), and
consolidation (maximum score, 3).
Progression of NTM-LD was defined as initiation of
anti-NTM treatment by the duty physician based on
symptomatic (e.g., increased amount of sputum) or
radiographic aggravation (e.g., cavity formation). Four of
the authors (Choi, J Lee, CH Lee, and Yim) participated
in the care of and discussed the treatment initiation for
each patient. Patients who refused treatment despite the
physician’s recommendation were also classified as hav-
ing disease progression.
Mycobacterial culture and Species identification of NTM
Acid-fast bacilli (AFB) smears and mycobacterial cul-
tures were performed as recommended in the standard
guidelines [16]. All cultures were grown in both solid
Ogawa media and the BACTEC MGIT 960 system.
NTM species were identified using sequence analysis of
the 16S rRNA gene by the algorithm descried in the
Clinical and Laboratory Standards Institute (CLSI)
guidelines [17]. Sequencing of the rpoB and tuf genes
was performed for further identification. In particular,
differentiation between M. abscessus and M. massiliense
was based on analysis of the rpoB gene sequence [18,
19]. Taxonomy of subspecies of the M. abscessus com-
plex was described based on recent suggestions [20]. Pa-
tients were considered to have a mixed NTM species
infection if NTM species other than the original one
were isolated at least twice during the follow-up period
until the start of treatment.
Statistical analysis
Baseline characteristics at the study initiation date (includ-
ing age, sex, comorbidities, symptoms at initial visit, ab-
normal breathing sound, anxiety, depression, St. George’s
Respiratory Questionnaire (SGRQ) score, chest CT score,
presence of cavities, pulmonary function, cholesterol and
albumin levels, body morphotype and composition) for
patients with and without disease progression were sum-
marized using descriptive statistics such as proportion,
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median and interquartile range (IQR). Continuous vari-
ables were categorized into tertiles (for example, body
morphotype and composition such as abdominal fat ratio)
or appropriate categorical variables based on normal range
(for example, albumin levels).
Cumulative disease progression was estimated using
the Kaplan-Meier method. A cox-proportional hazard
regression model was used to find predictors of disease
progression. Covariates with a p- value <0.2 were used
in multivariate analyses. Multivariate analyses were con-
structed using the stepwise backward elimination method,
which accounts for collinearity problems. All statistical




Since July 1st 2011, 207 patients with NTM-LD have
been enrolled into the original study. 51 patients without
follow up CT scans of the chest and six patients followed
up shorter than 6 months were excluded. Finally, data
for 150 patients were analyzed in the current study. The
median age of the 150 patients was 64 years, 92 patients
(61.3%) were female, and 110 (73.3%) were never
smokers (Table 1). Median height was 160.4 cm, median
weight was 54.1 kg, and median BMI was 21.1 kg/m2.
Median body fat and abdominal fat ratio were 13.5 kg
and 0.86 (Table 2).
Nontuberculous mycobacterial species isolated from
participants
MAC was most commonly isolated from participants:
M. avium (54 patients, 36.0%), M. intracellulare (40
patients, 26.7%), M. chimaera (1 patient, 0.7%), M.
yongonense (1 patient, 0.7%), M. avium and M. intra-
cellulare (10 patients, 6.7%), M. avium and M. chi-
maera (1 patient, 0.7%), and MAC and other species
(2 patients, 1.3%). M. abscessus complex (MABC) was
the second most common isolate: M. abscessus subsp.
abscessus (14 patients, 9.3%), M. abscessus subsp.
massiliense (12 patients, 8.0%), mix of both species (4
patients, 2.7%), and MABC and other species (1 pa-
tient, 0.7%) (Table 3).
Progression of nontuberculous mycobacterial lung disease
Median duration of follow-up of the 150 study partici-
pants was 28 months (IQR: 18 –36 months). During the
study period, NTM-LD progressed in 47 of 150 patients.
1- and 2-year disease progression rates were 18.2 and
28.1%, respectively (Fig. 1). Follow-up CT scans taken
before the initiation of treatment were available in 27 of
47 patients in whom NTM lung disease progressed. The
proportion of patients with radiographic worsening (de-
fined as a one-point increment in the CT score on
follow-up) was higher in the group that progressed
than in the group that did not progress (77.8 vs.
35.9%, P < 0.001) (Table 1).
Predictors of disease progression
Patients with progression of NTM-LD were younger
(62.0 vs. 66.0 years, p = 0.030), had higher SGRQ (24.4
vs. 19.8, p = 0.011) and chest CT (13 vs. 9, p < 0.001)
scores, and lower FVC (88 vs. 94%, p = 0.005) and albu-
min levels (4.2 vs. 4.3 g/dL, p = 0.031), compared with
those without progression (Table 1).
Univariate analysis was performed to find predictors of
disease progression. The lowest tertiles of weight, BMI,
waist and hip circumference, skeletal muscle mass, body
fat, and body fat percentage or abdominal fat ratio, were
related to progression of NTM-LD (Table 4). Additionally,
higher chest CT score, presence of cavities, serum albumin
level < 3.5 g/dL, and FVC < 80% were also associated with
disease progression.
The final multiple logistic regression model showed
that presence of cavities (adjusted hazard ratio [aHR],
4.577; 95% CI, 2.364–8.861), middle (aHR, 2.758; 95%
CI; 1.112–6.843) or low tertiles (aHR, 3.084; 95% CI,
1.241–7.668) of abdominal fat ratio, and albumin level
<3.5 g/dL (aHR, 12.943; 95% CI, 2.588–64.718) were as-
sociated with progression of NTM-LD (Table 5).
Serum adipokine levels
Serum leptin and adiponectin levels were not different
between patients with or without progression of NTM-
LD. However, the leptin/adiponectin ratio (0.58 vs.
0.94 ng/μg, p = 0.089) was lower, and the leptin normal-
ized to total body fat ratio was higher (0.60 vs. 0.53 ng/
mL/kg, p = 0.086) among patients with progression, al-
though statistical significance (p < 0.05) was not reached.
The adiponectin normalized to total body fat ratio was
higher among NTM-LD patients with progression (0.82
vs. 0.60 μg/mL/kg, p = 0.02) (Table 6).
Discussion
Through analysis of a cohort from a prospectively recruited,
observational study, we showed that body composition
(lower abdominal fat), radiographic feature (presence of
cavity), and nutritional status (low serum albumin level)
[21, 22] were associated with progression of NTM-LD.
Previous studies reported that presence of cavity [5]
and fibrocavitary form [10, 23] of NTM-LD were associ-
ated with disease progression. Our study confirmed
these previous observations and suggested that a higher
bacterial burden in the cavity could be the reason for
this association [24, 25].
Hypoalbuminemia is associated with increased complica-
tions and worse prognosis in various settings [22, 26–29].
Especially in patients with TB, a low albumin level was
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negatively associated with in-hospital death and 30-day sur-
vival [27]. Similarly, we demonstrated that hypoalbumin-
emia was associated with progression of NTM-LD.
Hypoalbuminemia could be the result of the combined ef-
fects of inflammation and malnutrition. A vicious cascade
of events ensues in which inflammation induces anorexia
and reduces the effective use of dietary protein as well as
augmenting the catabolism of the key somatic protein, al-
bumin [30]. Therefore, a low albumin level reflects severe
inflammation, which may affect disease progression.
Our study also showed that lower abdominal fat is as-
sociated with the progression of NTM-LD. In fact, previ-
ous studies reported that thinner chest subcutaneous fat
thickness or low BMI were a risk factor for radiologic
deterioration in MAC lung disease [9, 31]. Although dis-
ease progression could cause loss of fat, the fact that
self-reported BMI before diagnosis of NTM-LD was
lower among patients than in the general population
[11] suggests that a lower amount of fat could be a risk
factor for disease progression.
It has been recognized that adipose tissue participates
actively in inflammation and immunity, producing and
releasing a variety of pro-and anti-inflammatory factors
including adipokines, such as leptin and adiponectin
[32]. Previous studies reported higher serum levels of
adiponectin [33] or adiponectin normalized for total
body fat [12] among patients with NTM-LD than in
healthy controls. Our data also showed increased serum
levels of adiponectin normalized for total body fat and
decreased leptin/adiponectin ratios among patients in
whom NTM-LD progressed than in patients without
Table 1 Baseline characteristics of 150 participants with










Age, years 64 [55–72] 62 [54–68] 66 [56–74] 0.030
Sex, female 92 (61.3) 32 (68.1) 60 (58.3) 0.251
Smoking 0.160
Ever-smoker 40 (26.6) 9 (19.2) 31 (30.1)
Never-smoker 110 (73.3) 38 (80.9) 72 (69.9)
Past medical
history
Tuberculosis 55 (36.9) 20 (43.5) 35 (34.0) 0.267
Measles 29 (19.3) 7 (14.9) 22 (21.4) 0.352
Pertussis 7 (4.7) 3 (6.4) 4 (3.9) 0.678
Comorbidity
COPD 27 (18.8) 6 (12.8) 21 (21.6) 0.200
Asthma 4 (2.8) 0 (0) 4 (4.1) 0.304
Diabetes 14 (9.3) 5 (10.6) 9 (8.7) 0.765
Malignancy 20 (13.3) 4 (8.5) 16 (15.5) 0.241
Symptom at
initial visit
Cough 61 (40.7) 23 (48.9) 38 (36.9) 0.164
Sputum 108 (72.0) 35 (74.5) 73 (70.9) 0.649
Dyspneaa 15 (10.0) 3 (6.4) 12 (11.3) 0.392
Hemoptysis 29 (19.3) 13 (27.7) 16 (15.5) 0.081
Fever 19 (12.7) 5 (10.6) 14 (13.6) 0.614
Weight loss 17 (11.3) 8 (17.0) 9 (8.7) 0.138
Abnormal
breath sounds
20 (13.3) 9 (19.1) 11 (10.7) 0.157
Crackles 11 (7.3) 4 (8.5) 7 (6.8) 0.741
Wheezing 13 (8.7) 7 (14.9) 6 (5.8) 0.113
Anxietyb 29 (19.3) 11 (23.4) 18 (17.5) 0.394
Depressionb 41 (27.3) 16 (34.0) 25 (24.3) 0.213







135 (90) 41 (30.4) 94 (69.6)
Fibrocavitatary
disease
14 (9.3) 6 (42.9) 8 (57.1)
Unclassifiable 1 (0.7) 0 (0) 1 (1.0)
Chest CT scorec 10 [7–13] 13 [8–15] 9 [7–12] <0.001
Radiologic
deteriorationd
58/130 (44.6) 21/27 (77.8) 37/103 (35.9) <0.001
Presence of
cavity
37 (24.7) 24 (51.1) 13 (12.6) <0.001
Pulmonary
function
FVC, L 2.83 [2.32–3.42] 2.54 [2.23–3.16] 2.97 [2.36–3.48] 0.032
FVC, % 93 [81–101] 88 [79–95] 94 [82–106] 0.005
Table 1 Baseline characteristics of 150 participants with
nontuberculous mycobacterial lung disease at study entry
(Continued)
FEV1, L 2.09 [1.76–2.48] 2.11 [1.77–2.38] 2.08 [1.73–2.51] 0.532
FEV1, % 97 [82–110] 93 [82–105] 99 [81–113] 0.205
DLCO, % 93 [80–106] 93 [80–104] 93 [81–107] 0.998
Cholesterol,
mg/dL
182 [161–204] 178 [146–202] 183 [167–205] 0.229
Albumin,
g/dL
4.3 [4.0–4.4] 4.2 [4.0–4.4] 4.3 [4.1–4.5] 0.031
Data are presented as median [interquartile range] or proportion (%)
COPD, chronic obstructive pulmonary disease; SGRQ, St. George’s Respiratory
Questionnaire; CT, computed tomography; FVC, forced vital capacity; FEV1,
forced expiratory volume in 1 s; DLCO, diffusing capacity for carbon monoxide
aDyspnea was defined as modified Medical Research Council score ≥ 2
bHospital Anxiety and Depression Scale (HADS), same or > 8
cScores were given by considering the severity of bronchiectasis (maximum
score, 9), cellular bronchiolitis (maximum score, 6), cavity (maximum score, 9),
nodules (maximum score, 3) and consolidation (maximum score, 3). Maximum
score possible was 30
dRadiologic deterioration was defined as a one-point increment in the CT score
on follow-up CT scans of the chest. Follow-up CT scans taken before the initiation
of treatment were available in 27 out of 47 patients in whom nontuberculous
mycobacterial lung disease progressed
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progression. Previous reports and our study results sug-
gest that a lower amount of fat, possibly associated with
dysregulation of adipokines, may affect the development
and progression of NTM-LD. The precise mechanism of
these associations should be assessed in future studies.
Our study has some limitations. First, there is no glo-
bal consensus regarding the definition of NTM-LD pro-
gression. One study defined the progression of NTM-LD
as initiation of treatment [10], while another defined it
as radiologic deterioration [9]. We defined the progres-
sion of NTM-LD as treatment required for NTM-LD by
duty physicians. This could be a potential confounder
because physicians might be more likely to initiate treat-
ment for patients who are younger or patients with
MAC rather than MABC lung disease. Second, we did
not perform subgroup analysis according to each of
the NTM species because of the small number of pa-
tients in each group. Differences in terms of predictors
Table 2 Body morphotype and composition of 150 participants with nontuberculous mycobacterial lung disease at study entry
Total patients (N = 150) Progressed (N = 47) Not progressed (N = 103) p-value
Height, cm 160.4 [155.0–167.2] 159.0 [154.0–167.1] 162.0 [156.4–167.3] 0.227
Weight, kg 54.1 [49.1–60.0] 51.0 [45.0–57.0] 55.5 [50.0–61.8] 0.002
BMI, kg/m2 21.1 [19.3–22.8] 19.9 [18.5–21.7] 21.6 [19.8–23.2] 0.003
Waist, cm 76.0 [70.0–83.0] 72.0 [67.0–82.0] 77.0 [72.0–85.0] 0.008
Hip, cm 92.0 [89.0–97.0] 90.0 [88.0–92.0] 93.0 [90.0–97.0] 0.004
Skeletal muscle mass, kg 21.3 [19.0–24.4] 19.9 [17.3–22.5] 21.9 [19.6–24.7] 0.015
Body fat, kg 13.5 [10.1–17.4] 12.0 [9.1–13.8] 14.9 [11.0–18.5] 0.003
Body fat percentage, % 25.2 [20.2–30.4] 23.8 [18.6–26.0] 27.1 [20.4–31.0] 0.044
Abdominal fat ratio 0.86 [0.83–0.91] 0.85 [0.81–0.87] 0.87 [0.83–0.92] 0.004
Data are presented as median [interquartile range]
BMI, body mass index












M. avium 54 (36.0) 15 (31.9) 39 (37.9) 0.481
M. intracellulare 40 (26.7) 17 (36.2) 23 (22.3) 0.075
M. chimaera 1 (0.7) 0 (0) 1 (1.0) 1.000
M. yongonense 1 (0.7) 0 (0) 1 (1.0) 1.000
M. avium and
M. intracellulare
10 (6.7) 3 (6.4) 7 (6.8) 1.000
M. avium and
M. chimaera
1 (0.7) 1 (2.1) 0 (0) 0.313
MAC and othersa 2 (1.3) 1 (2.1) 1 (1.0) 0.530
M. abscessus complex (MABC)
M. abscessus subsp.
abscessus
14 (9.3) 4 (8.5) 10 (9.7) 1.000
M. abscessus subsp.
massiliense
12 (8.0) 3 (6.4) 9 (8.7) 0.754
M. abscessus subsp.
abscessus and massiliense
4 (2.7) 1 (2.1) 3 (2.9) 1.000
MABC and othersb 1 (0.7) 0 (0) 1 (1.0) 1.000
MAC and MABC 7 (4.7) 2 (4.3) 5 (4.9) 1.000
M. fortuitum 2 (1.3) 0 (0) 2 (1.9) 1.000
M. kyorinense 1 (0.7) 0 (0) 1 (1.0) 1.000
Data presented as n (%)
aOthers: M. fortuitum (1 patient), M. kansasii (1 patient)
bOthers: M. conceptionense (1 patient)
MAC, Mycobacterium avium complex; MABC, Mycobacterium abscessus complex
Fig. 1 Disease progression among 150 patients with nontuberculous
mycobacterial lung disease No difference was identified in progression
rate between patients with M avium complex (MAC) and M. abscessus
complex (MABC) (P = 0.323)
Kim et al. BMC Pulmonary Medicine  (2017) 17:5 Page 5 of 8





Q1 [<55, n = 31] Ref.
Q2 [55– 64, n = 40] 0.990 0.463–2.160 0.979
Q3 [65–72, n = 36] 1.052 0.480–2.309 0.899
Q4 [>72, n = 43] 0.429 0.169–1.089 0.075
Sex
Male Ref.
Female 1.351 0.731–2.496 0.337
SGRQ
< 25 Ref.
≥ 25 1.562 0.875–2.789 0.132
Radiologic feature
Nodular bronchiectatic disease 1
Fibrocavitary disease 1.740 0.737–4.108 0.206
Chest CT score
X Ref.
X + 1 1.211 1.123–1.306 <0.001
Presence of cavity
Absent Ref.
Present 3.750 2.086–6.739 <0.001
Cholesterol, mg/dL
≥ 200 Ref.
< 200 1.263 0.673–2.371 0.467
Albumin, g/dL
≥ 3.5 Ref.
< 3.5 8.942 3.097–25.818 <0.001
FVC, %
≥ 80 Ref.
< 80 1.974 1.049–3.715 0.035
FEV1
≥ 80 Ref.
< 80 1.102 0.546–2.226 0.786
Height, cm
High [>165, n = 48] Ref.
Middle [157–165, n = 55] 1.126 0.547–2.319 0.748
Low [<157, n = 47] 1.243 0.604–2.562 0.555
Weight, kg
High [>59, n = 49] Ref.
Middle [50–59, n = 55] 1.935 0.861–4.347 0.110
Low [<50, n = 46] 3.146 1.437–6.885 0.004
BMI, kg/m2
High [>22, n = 52] Ref.
Middle [20–22, n = 44] 1.619 0.669–3.752 0.261
Table 4 Predictors of disease progression: univariate analysis
(Continued)
Low [<20, n = 54] 3.211 1.538–6.705 0.002
Waist, cm
High [>80, n = 50] Ref.
Middle [72–80, n = 41] 1.082 0.467–2.507 0.853
Low [<72, n = 37] 2.183 1.041–4.575 0.039
Hip, cm
High [>95, n = 45] Ref.
Middle [90–95, n = 48] 2.062 0.890–4.780 0.092
Low [<90, n = 35] 2.485 1.041–5.929 0.040
Skeletal muscle mass, kg
High [>23, n = 41] Ref.
Middle [20–23, n = 43] 1.068 0.434–2.629 0.886
Low [<20, n = 44] 2.382 1.083–5.242 0.031
Body fat, kg
High [>16, n = 43] Ref.
Middle [11.5–16, n = 42] 2.565 1.045–6.300 0.040
Low [<11.5, n = 43] 3.068 1.270–7.409 0.013
Body fat percentage, %
High [>29, n = 42] Ref.
Middle [22.5–29, n = 40] 2.545 1.037–6.246 0.041
Low [<22.5, n = 46] 2.609 1.081–6.296 0.033
Abdominal fat ratio
High [>0.88, n = 51] Ref.
Middle [0.84–0.88, n = 39] 2.342 1.024–5.356 0.044
Low [<0.84, n = 38] 2.987 1.302–6.851 0.010
HR, hazard ratio; CI, confidence interval; SGRQ, St. George’s Respiratory
Questionnaire; CT, computed tomography; BMI, body mass index; FVC, forced
vital capacity; FEV1, forced expiratory volume in 1 s; Ref, reference
Table 5 Predictors of disease progression: multivariate analysis
Adjusted HR 95% CI p-value
Abdominal fat ratio
High [>0.88, n = 51] Ref.
Middle [0.84–0.88, n = 39] 2.758 1.112–6.843 0.029
Low [<0.84, n = 38] 3.084 1.241–7.668 0.015
Albumin, g/dL
≥ 3.5 Ref.
< 3.5 12.943 2.588–64.718 0.002
Presence of cavity
Absent Ref.
Present 4.577 2.364–8.861 <0.001
HR, hazard ratio; CI, confidence interval; Ref, reference
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for disease progression could exist among patients
with NTM-LD from different species. Lastly, because
we do not know the exact timing of NTM infection in
an individual patient, the risk factors for progression
elucidated could be the results of disease progression.
Conclusions
Progression of NTM-LD is associated with body com-
position in addition to presence of cavity and hypoalbu-
minemia. Lower abdominal fat ratio is an independent
predictor of NTM-LD progression.
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